Livzon Pharmaceutical Group Inc. (HKG:1513)
Hong Kong
· Delayed Price · Currency is HKD 27.95
0.00 (0.00%)
Apr 3, 2025, 4:08 PM HKT
HKG:1513 Revenue
In the year 2024, Livzon Pharmaceutical Group had annual revenue of 11.81B CNY, down -4.97%. Livzon Pharmaceutical Group had revenue of 2.73B in the quarter ending December 31, 2024, a decrease of -1.60%.
Revenue
11.81B CNY
Revenue Growth
-4.97%
P/S Ratio
n/a
Revenue / Employee
1.30M CNY
Employees
9,067
Market Cap
31.37B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.81B | -617.70M | -4.97% |
| Dec 31, 2023 | 12.43B | -199.54M | -1.58% |
| Dec 31, 2022 | 12.63B | 565.72M | 4.69% |
| Jan 1, 2022 | 12.06B | 1.54B | 14.67% |
| Jan 1, 2021 | 10.52B | 1.14B | 12.10% |
| Jan 1, 2020 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jan 1, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Alibaba Health Information Technology | 31.39B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |